Tivatrainer

Tivatrainer

Remimazolam Pk for children

Remimazolam Pk for children

Pharmacokinetics of remimazolam after intravenous infusion inanaesthetised children Yu-Qing Gao Harald Ihmsen , Zhi-Yan Hu, Wei Sun , Yu-Bo Fang, Zhen Wang, Jürgen Schüttler, Christian Jeleazcov and Hua-Cheng Liu From analysis of the use of the latest version of Tivatrainer we know that many simulations are done with the relative new sedative

Tranexamic Acid(Grassin-Delyle) validation

The anti-fibrinolytic drug tranexamine acid(TA) is a useful drug for limiting bloodloss in major surgical operations like cardiac surgery. Grassin-Delyle and co-authors promote the use of a relative high dose, aiming at a concentration of 150 µg/ml. This concentration should be maintained during the whole surgical procedure. They

Remimazolam

Remimazolam: a benzodiazepine like midazolam with engineered pharmacokinetic properties like remifentanil:metabolized by hydrolysis by non specific tissue and plasma esterases. However it seems that a carboxylesterase in the liver is the main responsible for the metabolization. The pharmacokinetics have been described in multiple publication but only recent a population

Validation Eleveld propofol in Tivatrainer(X)

Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation D. J. Eleveld, P. Colin, A. R. Absalom and M. M. R. F. Struys Pump manufacturers have implemented, or are considering implementation, of the above model. The parameterisation of the model is rather complex but is available in TivatrainerX

Models, models and more models

Models, models and more models

After the era where Target Controlled Infusion was finally called Totally Confused Infusion because of the turmoil of models that were offered by the different pump manufactures for propofol: Marsh, Marsh with short keo, Schnider with fixed time to peak effect, Schnider with fixed keo, and Paedfusor,Kataria for children.

TivatrainerX: validation Remifentanil Kim-Obara-Egan

Disposition of Remifentanil in Obesity A New Pharmacokinetic Model Incorporating the Influence of Body Mass Tae Kyun Kim, M.D., Shinju Obara, M.D., Talmage D. Egan, M.D., and the Remifentanil Pharmacokinetics in Obesity Investigators (Anesthesiology 2017; 126:1019-32) When a pharmacokinetic or pharmacodynamic model is implemented in simulation